🔗 Share this article

As the US proceeds with unprecedented changes to its vaccination schedules, a particular individual appears unexpectedly: Høeg, an American of Danish descent sports physician and epidemiologist who rose to prominence by questioning COVID-19 vaccinations in the global health crisis and has concentrated on potential fatalities following COVID-19 immunization in her recent tenure at the Food and Drug Administration.

Planned Shifts to Pediatric Immunization Program

Health officials were set to announce sweeping changes to the pediatric immunization program earlier this month, aligning the US with the Danish vaccine program, according to reports – a major change that would place the US out of alignment with a large portion of the world with little proof for public health gain. This reveal has been postponed until the next year.

In place of the top vaccines chief, Tracy Beth Høeg is listed to present at the gathering. She was recently named interim head of the FDA’s CDER, the fifth appointee to head the office this calendar year.

Consolidating Power at the FDA

The acting appointment could signify a closer partnership between the pharmaceutical and biologics branches as Høeg and Prasad solidify control at the agency – and it suggests a renewed priority upon reevaluating previously authorized vaccines at the FDA.

Høeg has repeatedly called for discontinuing certain childhood vaccine recommendations in the US in order to be more in line with the Danish model, a nation with comprehensive healthcare and a population roughly the size of the state of Wisconsin.

So far public appearances, she has continued to focus on immunizations – typically the responsibility of Prasad, head of the FDA’s vaccine center – instead of drug regulation.

Questions Over Background

The appointee has no obvious track record in drug development, regulation or management, which has been standard for former heads of the biologics center. She has worked at the FDA as a top consultant to the agency head and the vaccine center since spring.

“She doesn’t seem to have the requisite experience” for overseeing the pharmaceutical oversight division, remarked a neurologist and psychiatrist. “She’s never run a randomized controlled trial. She lacks experience in managing a sizeable institution. She lacks background in drug approvals.”

Previous directors of CBER would “understand laws and regulations and the underlying principles of pharmaceutical innovation”, noted Dr. Janet Woodcock. “Clearly, she lacks the type of experience that previous people who ran the center have had.”

CDER has an enormous workload at the agency, Woodcock emphasized.

“The public just pays attention on the new drug program, but the generic program approves a multitude of generic drugs. There’s a biosimilars division, OTC medication office and so forth, and each of these have to be managed,” she said. “The responsibility you overlook, that is precisely what that I always told people is going to cause problems.”

There is also, a significant leadership component to the role, which supervises in excess of 5,000 employees. “It is a massive management job, if you perform it correctly,” she added.

Response and Contentious Programs

Regarding inquiries about Høeg’s credentials and whether this selection represents increased cooperation among agency officials on vaccines, a representative stated that the “inquiries are based on inaccurate presumptions”.

“Her resume aligns with the duties of her role,” the official stated, citing the time Dr. Høeg spent guiding the agency head on “drug safety and regulatory science, including computerized risk analysis and immunization monitoring”.

In her interim role, Dr. Høeg assumes responsibility for the commissioner’s new expedited review system, a contentious rapid drug-approval program that apparently troubled her predecessors. “How are these therapies being selected for this fast-track system? Who is making the choices?” Dr. Howard said. “There’s a lot of lack of transparency occurring at the FDA right now.”

Overall, he stated, “the FDA appears to be shifting towards less stringent rules of all drugs, aside from immunizations.”

Established Track Record on Vaccines

Concerning immunizations, Høeg has a more established, if troubling, history, some experts said. She released a research paper using unconfirmed volunteer-provided data to assess the frequency of heart inflammation after Covid vaccination. She counseled the state of Florida surgeon general Joseph Ladapo, who reportedly have altered data to suggest COVID-19 vaccinations are riskier than they are.

Part of her “desired changes” for the incoming administration featured revising regulations for new vaccines and discontinuing “optional” vaccines, she stated after the election on a online show. At the agency, Dr. Høeg has allegedly suggested barring young men from receiving COVID-19 vaccines.

“She’s an thorough ideologue who begins with her beliefs and works backwards to accommodate the data in a extremely deceptive, dishonest fashion,” Howard said.

Consolidating Power and a “Revenge Tour”

Dr. Høeg joined fellow dissenters, {like|